[Federal Register Volume 67, Number 80 (Thursday, April 25, 2002)]
[Notices]
[Page 20542]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-10116]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Synthetic Ordered Arrays 
of Antigen for the Induction of Autoantibodies

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the invention embodied in United 
States Patent Application 09/835,124 and its foreign equivalents, 
entitled ``Virus-Like Particles for the Induction of Autoantibodies,'' 
filed on April 13, 2001, with priority back to U.S. S/N 60/105,132, 
filed October 21, 1998, to LigoCyte Pharmaceuticals, Inc., having a 
place of business in Bozeman, Montana. The patent rights in this 
invention have been assigned to the United States of America.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before June 24, 
2002, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Peter Soukas, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; e-mail: [email protected]; telephone: (301) 496-
7056, ext. 268; facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: This invention claims compositions and 
methods for producing antibodies to tolerogens (self-antigens normally 
exposed to B cells that fail to induce an antibody response). The 
compositions of the invention comprise multiple copies of a tolerogen 
(or at least one B cell epitope of a tolerogen) chimerized to 
capsomeric structures or capsid proteins in an orderly manner. This 
invention could potentially replace any treatment utilizing chronic 
administration of a monoclonal antibody that reacts with a self-
antigen.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use may be limited to non-Virus-Like Particle (VLP) 
polyvalent liposome nanoparticle vaccines against self-antigens.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 17, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-10116 Filed 4-24-02; 8:45 am]
BILLING CODE 4140-01-P